Alterome Therapeutics, Inc.
Clinical trials sponsored by Alterome Therapeutics, Inc., explained in plain language.
-
New targeted drug aims to shrink hard-to-treat tumors with AKT1 mutation
Disease control Recruiting nowThis early-phase trial tests an experimental drug called ALTA2618 in about 110 adults whose advanced solid tumors (like breast or endometrial cancer) have a specific AKT1 E17K gene change. The main goal is to check the drug's safety and find the right dose. Participants must have…
Phase: PHASE1 • Sponsor: Alterome Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
New drug targets tough cancers with KRAS mutation
Disease control Recruiting nowThis early-stage trial tests a new drug called ALTA3263 in adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a KRAS mutation. The main goals are to check safety and find the right dose. About 188 people whose cancer has worsened after stand…
Phase: PHASE1 • Sponsor: Alterome Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 02:48 UTC